-
Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention
Infectious Disease Frontier: Neurosyphilis is one of the most severe clinical forms of syphilis. What are the challenges in the diagnosis and treatment of Neurosyphilis? Dr. Khalil Ghanem: The main…
-
Application of carbapenems in the treatment of MDR-GNB and management of drug resistance
Infectious Disease Frontier: Could you share the unique advantages of Carbapenem antibiotics in treating multi-drug resistant Gram-negative infections, and do these advantages justify their use as a first-line treatment? Dr.…
-
Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive
The American Society for Radiation Oncology (ASTRO) Annual Meeting took place in Washington, D.C., from September 29,2024 to October 2,2024. As one of the most prestigious annual events in radiation oncology, ASTRO offers a platform to share the latest advances, focusing on radiotherapy as a primary treatment for various cancers, alongside key updates in technology…
-
Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer
The data of the KEYNOTE-A18 study disclosed at the Presidential Symposium I of the 2024 ESMO Congress shows that the overall survival (OS) of newly diagnosed patients with locally advanced cervical cancer who received pembrolizumab and concurrent chemoradiotherapy (CRT) is significantly improved (abstract number 709O). The 36-month OS rate of pembrolizumab + concurrent CRT treatment…
-
ESMO 2024丨Dr. González-Martín interprets the final analysis results of the PRIMA/ENGOT-ov26/GOG-3012 study
Dr. Antonio González-Martín from the Cancer Center Clínica Universidad de Navarra in Spain presented the results of the phase III PRIMA/ENGOT-OV26/GOG-3012 study (abstract number LBA29) at the 2024 ESMO Congress. For patients with advanced ovarian cancer with homologous recombination deficiency (HRd), the possibility of progression-free survival after treatment with niraparib is twice that of placebo,…
-
ESMO 2024 丨 Dr. Jennifer Chan: The CABINET trial adds a major new treatment “weapon” for patients with advanced neuroendocrine tumors
The CABINET study (abstract number 11410), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), updated the latest results of cabozantinib versus placebo in the treatment of advanced neuroendocrine tumors (NETs) after progression following previous treatment. At the conference site, we specially invited the Principal Investigator, Dr. Jennifer Chan from…
-
Dr. Lorenza Rimassa: The 5-year OS update of the HIMALAYA study sets a new high for survival in first-line treatment of advanced liver cancer
Immunotherapy for advanced liver cancer has advanced rapidly and has become a standard first-line treatment. A HIMALAYA study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the new immunotherapy combination STRIDE—tremelimumab and durvalumab compared with sorafenib. Dr. Lorenza Rimassa, the Principal Investigator from Humanitas University in Italy, was…
-
Advancing Treatment in #TripleNegativeBreastCancer : Insights from the Keynote 522 Trial
We are pleased to share an expert discussion with Dr. Peter Schmid on the findings from the pivotal Keynote 522 trial. This landmark Phase 3 study investigates the impact of combining chemotherapy with immunotherapy (Pembrolizumab) in early-stage triple-negative breast cancer (TNBC). The trial’s results highlight a 34% reduction in the risk of death, marking a…
Connecting Medical Expertise through Media